Literature DB >> 1987703

Beneficial and detrimental effects of RBC-adsorbed antilymphocyte globulin and prednisone on purified canine islet autograft and allograft function.

D B Kaufman1, P Morel, R Condie, M J Field, M Rooney, P Tzardis, P Stock, D E Sutherland.   

Abstract

We have examined the effects of prednisone, cyclosporine, azathioprine, and RBC-adsorbed goat antidog antilymphocyte globulin on islet graft function in totally pancreatectomized canines with purified, quantitatively defined, autologous, or allogeneic islets transplanted to the liver. The objectives were twofold: (1) to determine the potential detrimental effects to islet autograft function of the aforementioned agents, and (2) to determine the relative efficacy of the "nontoxic" agents in prolonging purified islet allograft function administered in doses that would be considered tolerable in human. The islet autograft studies demonstrated that prednisone given in doses of 1-2 mg/kg/day had a detrimental effect on islet autograft function, and that the combinations of immunosuppression involving CsA, azathioprine, and ALG were not detrimental to islet autograft function to the extent that hyperglycemia would ensue. In the subsequent allograft studies, three groups of canines received islet transplants: (1) controls (n = 5; 7860 +/- 750 islets/kg/weight), (2) canines given CsA and azathioprine (n = 6; 6810 +/- 890 islets/kg/body weight), and (3) canines given CsA, azathioprine, and RBC-adsorbed goat antidog ALG (n = 8; 6540 +/- 710 islets/kg/body weight). The mean (+/- SE) day of rejection (serum glucose greater than or equal to 200 mg/dl) in the group of canine islet allograft recipients receiving CsA, azathioprine, and ALG was 11.8 +/- 1.4 days--significantly prolonged versus islet allograft recipients receiving no immunosuppression (mean survival 4.8 +/- 1.1 days, P less than 0.03), and versus allograft recipients receiving CsA/azathioprine without ALG (mean survival 4.4 +/- 1.4 days, P less than 0.05). Prednisone appears to be detrimental to islet graft function, even at low doses. ALG was not toxic, and significantly extended the survival of canine islet allografts. The inclusion of steroids as part of maintenance immunosuppression, or as treatment for acute rejection of islets, in human islet transplants should be reconsidered, whereas ALG or other antilymphocyte agents should continue to be used.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1987703     DOI: 10.1097/00007890-199101000-00005

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  Outcome of human islet isolation and allotransplantation in 20 consecutive cases.

Authors:  C Ricordi; P Carroll; A Tzakis; Y Zeng; H L R Rilo; R Alejandro; R Shapiro; J J Fung; A J Demetris; D H Mintz; T E Starzl
Journal:  Diabetes Nutr Metab       Date:  1992

2.  Deterioration of glycemic control after corticosteroid administration in islet autotransplant recipients: a cautionary tale.

Authors:  Anh Ngo; David E R Sutherland; Gregory J Beilman; Melena D Bellin
Journal:  Acta Diabetol       Date:  2011-08-07       Impact factor: 4.280

Review 3.  Clinical islet transplantation.

Authors:  Dixon B Kaufman; William L Lowe
Journal:  Curr Diab Rep       Date:  2003-08       Impact factor: 4.810

Review 4.  Clinical islet cell transplantation. Are we there yet?

Authors:  L Rosenberg
Journal:  Int J Pancreatol       Date:  1998-12

5.  Human islet isolation and allotransplantation in 22 consecutive cases.

Authors:  C Ricordi; A G Tzakis; P B Carroll; Y J Zeng; H L Rilo; R Alejandro; A Shapiro; J J Fung; A J Demetris; D H Mintz
Journal:  Transplantation       Date:  1992-02       Impact factor: 4.939

6.  The effect of prednisone on pancreatic islet autografts in dogs.

Authors:  Y Zeng; C Ricordi; J Lendoire; P B Carroll; R Alejandro; D R Bereiter; A Tzakis; T E Starzl
Journal:  Surgery       Date:  1993-01       Impact factor: 3.982

7.  Ciclesonide activates glucocorticoid signaling in neonatal rat lung but does not trigger adverse effects in the cortex and cerebellum.

Authors:  Juliann D Jaumotte; Alexis L Franks; Erin M Bargerstock; Edwina Philip Kisanga; Heather L Menden; Alexis Ghersi; Mahmoud Omar; Liping Wang; Anthony Rudine; Kelly L Short; Neerupama Silswal; Timothy J Cole; Venkatesh Sampath; A Paula Monaghan-Nichols; Donald B DeFranco
Journal:  Neurobiol Dis       Date:  2021-06-11       Impact factor: 7.046

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.